Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a trial.
A first-of-its-kind cancer vaccine is helping significantly reduce the chances that melanoma patients' tumors return.
Because they can be developed rapidly, mRNA vaccines have the potential to bring personalized care, while others can be ...
When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage ...
Personalized mRNA vaccines against melanoma—the deadliest form of skin cancer—reduced the risk of death or recurrence by 42 ...
When COVID-19 vaccines first rolled out, pregnant women were largely left out of the original clinical trials, leaving them ...
8d
Head-to-head comparison of three mRNA vaccines reveals differences in their stability in human blood
A study by Australian researchers compared three mRNA-LNP vaccine platforms in human blood samples, generating findings that ...
Michael Mina, MD, PhD, explains LIBERTY trial findings on VYD2311 tolerability alone and given with an mRNA COVID-19 vaccine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results